In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02811523 |
Recruitment Status :
Recruiting
First Posted : June 23, 2016
Last Update Posted : November 27, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Sarcoma which has spread to the lungs is most often treated with surgery. Even with surgery, most patients will not be cured and will die from their disease, probably because of small cancer cells that are present in the lungs at the time of surgery, but cannot be seen or detected. It is for this reason that we are looking for a better treatment. Giving chemotherapy after surgery is generally not recommended because it has significant side effects and no benefit has been proven.
This study is investigating a new technique for delivering chemotherapy directly into the lungs at the time of surgery. Delivering chemotherapy directly to the lungs could potentially kill any microscopic cancer cells that are present in the lungs at the time of surgery, while sparing other major organs in the body from the side effects of chemotherapy. This technique is called In Vivo Lung Perfusion (IVLP). This is a Phase I, non-randomized, dose escalation study that will act as a pilot study for a larger prospective, multicenter, controlled clinical trial. Patients who have bilateral disease will have one lung undergo IVLP and the other lung will remain untreated with the IVLP (the other lung will be treated as current standard of care - either surgery or radiation) as a control lung. The patients will undergo a posterolateral thoracotomy. Lung metastases will be identified by visualization or palpation. After surgical isolation of the lung by proximal control of pulmonary artery and veins, IVLP will be initiated. After 3 hours of IVLP, the lung metastases will be removed in the usual fashion. Patients will be cared for post-surgery according to institutional standards. The patients will be followed for up to 2 years. The primary endpoint is safety. Secondary endpoints include additional safety endpoints and efficacy.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bone Sarcoma Soft Tissue Sarcoma Pulmonary Metastases | Drug: Doxorubicin | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 11 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues Sarcomas |
Study Start Date : | February 2016 |
Estimated Primary Completion Date : | February 2024 |
Estimated Study Completion Date : | February 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: Doxorubicin 5 mcg/ml
Doxorubicin 5mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
|
Drug: Doxorubicin
Doxorubicin by In Vivo Lung Perfusion |
Experimental: Doxorubicin 7 mcg/ml
Doxorubicin 7mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
|
Drug: Doxorubicin
Doxorubicin by In Vivo Lung Perfusion |
Experimental: Doxorubicin 9 mcg/ml
Doxorubicin 9mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
|
Drug: Doxorubicin
Doxorubicin by In Vivo Lung Perfusion |
Experimental: Doxorubicin 11 mcg/ml
Doxorubicin 11mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
|
Drug: Doxorubicin
Doxorubicin by In Vivo Lung Perfusion |
Experimental: Doxorubicin 13 mcg/ml
Doxorubicin 13mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
|
Drug: Doxorubicin
Doxorubicin by In Vivo Lung Perfusion |
Experimental: Doxorubicin 15 mcg/ml
Doxorubicin 15mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
|
Drug: Doxorubicin
Doxorubicin by In Vivo Lung Perfusion |
Experimental: Doxorubicin 17 mcg/ml
Doxorubicin 17mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
|
Drug: Doxorubicin
Doxorubicin by In Vivo Lung Perfusion |
Experimental: Doxorubicin 20 mcg/ml
Doxorubicin 20mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
|
Drug: Doxorubicin
Doxorubicin by In Vivo Lung Perfusion |
- Safety of IVLP at selected dose levels by acute lung injury findings [ Time Frame: Up to 2 years ]
- Maximal tolerated dose by using a titration design [ Time Frame: Up to 2 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 64 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of Soft Tissue or Osteogenic Sarcoma
- Presence of bilateral pulmonary metastases
- 3 or more lung lesions in total
- Age less than 65 years
- ECOG 0-2
- Absence of extra-pulmonary disease
- Contralateral disease amenable to surgery or radiation
- All lung lesions in the lung to be treated with IVLP can be resected with wedge or segmental resections (non-IVLP treated lung will be treated with radiation or surgery 4-12 weeks prior to IVLP)
Exclusion Criteria:
- Patient has previously received more than 450 mg of doxorubicin
- Left Ventricular Ejection Fraction <50%
- History of significant pulmonary disease or pneumonitis
- Pregnant or lactating females
- Age 65 years or older, or less than 18 years
- Inability to understand the informed consent process
- Hypersenstivity to doxorubicin
- Current participation in another therapeutic clinical trial
- Previous lung metastatectomy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02811523
Contact: Marcelo Cypel, M.D. | 416-581-7773 | marcelo.cypel@uhn.ca | |
Contact: Jennifer Lister, BSc CCRP | 416-340-4857 | Jennifer.Lister@uhn.ca |
Canada | |
Princess Margaret Cancer Centre | Recruiting |
Toronto, Canada | |
Contact: Marcelo Cypel, M.D. 416-581-7773 marcelo.cypel@uhn.ca |
Principal Investigator: | Marcelo Cypel, MD | University Health Network, Toronto |
Responsible Party: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT02811523 |
Other Study ID Numbers: |
15-8820 |
First Posted: | June 23, 2016 Key Record Dates |
Last Update Posted: | November 27, 2019 |
Last Verified: | November 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Neoplasm Metastasis Sarcoma Osteosarcoma Lung Neoplasms Neoplastic Processes Neoplasms Pathologic Processes Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms, Bone Tissue Neoplasms, Connective Tissue Respiratory Tract Neoplasms |
Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases Doxorubicin Antibiotics, Antineoplastic Antineoplastic Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |